In the United States, home health and hospice companies are experiencing strong M&A activity. Owners considering a sale often ask: What will my business sell for?
The Valuation Equation
The foundation of healthcare M&A valuation is straightforward:
Value = Adjusted EBITDA × Valuation Multiple
The challenge lies in defining Adjusted EBITDA and determining the right multiple based on market conditions and buyer appetite.
Adjusted EBITDA Explained
EBITDA reflects profitability, but adjustments for non-recurring or non-essential costs provide a truer measure. Documenting addbacks can strengthen the case for a higher valuation.
The Impact of Time Frames
Buyers may calculate EBITDA using trailing twelve months (TTM), year-to-date annualization, or shorter trailing periods. Each approach can influence reported earnings and valuations.
Multiples and Market Factors
Valuation multiples in healthcare M&A typically range from 3× to 10×, with motivated or synergistic buyers often paying at the higher end. Market position, service lines, and geography all influence the range.
Buyer-Specific Synergies
Synergies vary by buyer and are not included in Adjusted EBITDA. For instance, a buyer able to eliminate overhead costs may view a business as more valuable, supporting a higher multiple.
Key Insight for US Owners
Valuation is shaped by both financial performance and buyer perception. Knowing how EBITDA is calculated and identifying the right buyer are critical to achieving a premium outcome.
Aspen Valuations advises US healthcare owners on M&A, helping them understand valuation drivers and maximize results in the sale process.